The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.
Fox Business on MSN
Pfizer CEO addresses growing competition in weight-loss drugs
Pfizer CEO Albert Bourla discusses Pfizer’s Q4 adjusted earnings and the competitive landscape for weight-loss drugs on ‘The ...
Also: All the news and watercooler chat from Fortune.
Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is the ...
Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 ...
Pfizer shares fell 3.3% Tuesday on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war ...
A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. government’s ...
Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its ...
SAN FRANCISCO, Jan 12 (Reuters) - Pfizer (PFE.N), opens new tab is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results